MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: Results of a Phase I trial

Emanuela Romano, Olivier Michielin, Verena Voelter, Julien Laurent, Hélène Bichat, Athina Stravodimou, Pedro Romero, Daniel E. Speiser, Frédéric Triebel, Serge Leyvraz*, Alexandre Harari

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

57 Scopus citations

Fingerprint

Dive into the research topics of 'MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: Results of a Phase I trial'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds